India, February 10th, 2026:  In a major step towards transforming the treatment landscape for high burden diseases such as cancers and autoimmune disorders, Immuneel Therapeutics Private Limited  and Manas AI, Inc. are entering into a strategic partnership to evaluate the potential application of AI-native tools within the landscape of biologics, antibody-drug conjugates (ADCs), novel allogeneic and in vivo gene-based therapies. This collaboration aims to assess how Immuneel may leverage Manas AI’s neuro-symbolic models to facilitate the ability to develop and deliver advanced treatments affordably and at scale rapidly.

The integration of Immuneel’s research & development, translational and GMP-grade biomanufacturing capabilities with Manas AI’s AI-native discovery engine, aims to shorten development timelines and accelerate access to therapies that can change the course of disease and improve quality of life.

The collaboration has the potential to span multi-specific antibody designs, AI-optimized binders, payload/linker discovery for ADCs, manufacturability screening, and next-generation allogeneic and in vivo delivery approaches. These capabilities are critical for creating medicines that are not only scientifically advanced but also safer, more scalable, and financially accessible.

Together, the companies intend to determine if a feedback loop—from AI-driven in silico design to development, preclinical testing and scalable manufacturing—can be effectively established and ultimately enable faster iteration, better predictability, and more audit-ready development pathways.

Kiran Mazumdar‑Shaw, Co‑founder & Board Director, Immuneel Therapeutics said, “Immuneel was founded to make advanced cell and gene based therapies accessible to patients who need them most. By pairing Immuneel’s integrated platform with Manas AI’s cutting‑edge discovery, this partnership unites complementary strengths in innovation and translation. Our goal is to lower barriers to care while upholding the highest standards of quality, safety, and affordability.”

Amit Mookim, Chief Executive Officer, Immuneel Therapeutics said, “By combining Immuneel’s Research & Development, clinical‑grade manufacturing and translational pathway with Manas AI’s discovery engine, we aim to compress development timelines and strengthen a new paradigm for safer, more effective assets that can reach patients sooner—without compromising outcomes or affordability.”

Dr. Siddhartha Mukherjee, Co-founder, Immuneel Therapeutics; Founder & CEO, Manas AI said, “At Manas AI, we believe AI-guided design has the capacity to materially improve the precision, potency, and safety of next generation biologics, ADCs, and in vivo gene-based therapies. Partnering with Immuneel enables preliminary, side by side evaluation—from computational selection and biophysical validation to preclinical screening—with the goal of responsibly advancing multi-specific designs, optimized linker/payload pairs, and in vivo delivery, at speed.”